The 35th Annual EAU Congress was held between 17 and 26 July and consisted of the 3-day EAU20 Virtual Congress and 7-day Theme week. This year’s Annual EAU Congress was supposed to be held in Amsterdam. However, due to the COVID-19 pandemic, the congress went virtual for the first time.
The congress provided state-of-the-art urological science and education and comprised hot topics, cutting edge science, and important updates in a mix of oncology and non-oncology sessions.
New urosepsis data of the prospective observational SERPENS study indicated the use of early selective antibiotic therapy.
The phase 3 KEYNOTE-426 trial demonstrated a significant survival advantage for patients with metastatic renal-cell carcinoma receiving pembrolizumab and axitinib with no difference in quality of life compared with sunitinib.
A debate was held on upfront cytoreductive nephrectomy in renal cancer surgery, confirming its role in patients that do not deserve immediate medical treatment.
The large IRON study demonstrated that robot-assisted partial nephrectomy is associated with lower morbidity and similar oncologic and long-term renal function outcomes compared with open partial nephrectomy.
A post-hoc analysis of the phase 3 NIMBUS trial demonstrated that reducing the frequency of BCG instillations during induction and maintenance is inferior to the standard BCG schedule regarding time to first recurrence of non-muscle invasive bladder cancer. The ProPSMA study showed that PSMA PET-CT staging is 27% more accurate than conventional imaging.
This report will outline the highlights discussed at the conference. Besides the subjects indicated above, this includes interesting findings in oncological and functional urology, stones, imaging, LUTS, and much more. We hope that you will enjoy reading this Conference Report!
Prof. Hendrik Van Poppel
Hendrik Van Poppel, MD, PhD, graduated in General Surgery and in Urology and received his postgraduate training in London, Barcelona, Copenhagen, Mainz, and Rotterdam. He obtained a PhD in Medical Sciences in 1988. He became a Fellow of the European Board of Urology in 1992, full Professor of Urology in 1993, and chair of the department of urology in Leuven in 2002.
He was Director of the European School of Urology for 8 years before becoming EAU Adjunct Secretary General, responsible for Education, in 2012. During his mandate he started the set-up of new EAU Offices for Patient affairs and for European political business in Brussels.
Prof. Van Poppel attended more than EAU 2016 München 1000 scientific meetings and gave 900 lectures at national and international podia. He has published 221 papers as first author on uro-oncology and has co-authored more than 480 and (co-)edited several books on kidney and prostate cancer. He is reviewer and editorial Board Member for more than 30 urological and uro-oncological journals.
He received the Distinguished Career Award of the Société Internationale d’Urologie (SIU) in Buenos Aires in 2016 and the Frans Debruyne Life time achievement award of the EAU in 2020.
Conflict of Interest Statement: Nothing to disclose
©2016 Edwin van Wijk
« New lithotripter data: improved stone clearance Next Article
Radiation stewardship for patient and endourologist »
Table of Contents: EAU 2020
Letter from the Editor
EAU 2020 Highlights Podcast
Surgical Techniques and Safety
The new adjustable artificial sphincter victo: Surgical technique and results after a follow-up of more than one year
New urosepsis data from the SERPENS study
Intra-operative cone-beam computed tomography for detecting residual stones in percutaneous nephrolithotomy
Pressure and temperature: do high-power lasers pose a threat?
Radiation stewardship for patient and endourologist
New lithotripter data: improved stone clearance
Beyond the limits of ultrasound: Three dimensional augmented reality robot assisted partial nephrectomy (3D AR-RAPN) for complex renal masses
Imaging guided surgery with augmented reality for robotic partial nephrectomy
KEYNOTE-426: no QoL differences pembrolizumab + axitinib versus sunitinib
Debate: upfront cytoreductive nephrectomy or not?
Robotic-assisted partial nephrectomy: lower morbidity
Reduced BCG frequency, faster NMIBC recurrence
Nadofaragene firadenovec effective in BCG-unresponsive papillary NMIBC
Understanding MIBC biology for novel treatment options
Prostate Cancer & Imaging
Transperineal laser ablation of prostate
Prostatectomy: R-LRPE better than LRPE for continence
PSMA PET-CT staging is 27% more accurate
Docetaxel + hormonal therapy: improved prostate cancer PFS
ARAMIS subgroup analysis: darolutamide benefits across PSADT groups
Large patient-driven survey reveals QoL issues after prostate cancer treatment
Targeting steroid sulphatase in resistant prostate cancer cells
Good tolerance of post-RP radiotherapy ± short-term ADT
BPH & LUTS
Minimizing post-operative stress urinary incontinence after HoLEP: Our preliminary experience and short-term results of ‘’En Bloc’’ technique with early apical release
LUTS 2-year outcomes: aquablation versus TURP
HoLEP versus PVP in prospective randomised trial
LUTS in the neuro-urologic patient
Testis Cancer & Andrology
Peyronie’s disease: surgical options
Infertility and testis cancer risk: causal or association?
32% more men complain of reduced sex drive in 2019 versus 2009
Best of EAU: Updates on imaging and treatment of prostate cancer